USFDA completes inspection of Lupin’s Nagpur plant

New Delhi: Pharma major Lupin today said the US health regulator has completed inspection of its Nagpur facility without making any observations.

In a BSE filing, Lupin “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations”.

Lupin said its Nagpur facility manufactures oral solid products.

Shares of Lupin were trading 2.09 per cent higher at Rs 767.50 on BSE.

  • Related Posts

    • Pharma
    • May 31, 2025
    • 186 views
    Generic drugs can bring hope for SMA patients’

    Dr Ann Agnes Mathew, a consultant paediatric neurologist and neuromuscular specialist based in Bengaluru, treats nearly 600 SMA patients from across India. In an interview with DH’s Udbhavi Balakrishna, she…

    • Pharma
    • May 31, 2025
    • 163 views
    47% of pharma MOUs from VGGS 2024 commissioned

    Gandhinagar:  The state govt said that 47% of MoUs signed in the pharmaceutical sector in the Vibrant Gujarat Global Summit (VGGS) 2024 have been commissioned. It said on Friday that…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Generic drugs can bring hope for SMA patients’

    Generic drugs can bring hope for SMA patients’

    47% of pharma MOUs from VGGS 2024 commissioned

    47% of pharma MOUs from VGGS 2024 commissioned

    I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

    I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

    AstraZeneca gets CDSCO nod for lung cancer drug

    AstraZeneca gets CDSCO nod for lung cancer drug